2015 Fiscal Year Final Research Report
Optimization of medical treatments: Reassessment of hormone data in patients with the autoantibodies
| Project/Area Number |
25460232
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Ritsumeikan University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
Shimatsu Akira 京都医療センター, 臨床研究センター, 臨床研究センター長 (90196494)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | ホルモン自己抗体 / 甲状腺刺激ホルモン / プロラクチン / インスリン / マクロプロラクチン血症 / マクロ TSH / 潜在性甲状腺機能低下症 / 糖尿病 |
|---|
| Outline of Final Research Achievements |
Macro TSH was found in 0.5% of patients with subclinical hypothyroidism. The size of macro TSH was >150kDa compared with 28kDa of monomeric TSH. Macro TSH was mostly a complex of TSH with IgG and the bioactivity was found low by the experiment using FRTL5. Three commercially available TSH assay systems (Elecsys, Centaur, Architect) all recognized macro TSH. It was recommended to screen macro TSH before initiating thyroid hormone replacement therapy. Non-IgG type macroprolactin was found to cross-react to Architect assay system that reportedly seldom recognized macroprolactin. Insulin glargine and aspart were found to be more antigenic and be prone to produce anti-insulin antibody in patients with diabetes on insulin therapy.
These antibodies should be examined to understand the pathophysiology and to provide better treatments for many patients.
|
| Free Research Field |
内分泌学（GH, PRL, TSH)、薬物治療学
|
